Adaptimmune Therapeutics PLC — Director's Dealing 2019

Sep 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-09-01

Reporting Person: Rawcliffe Adrian (Director, CEO and CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-09-01	Option to purchase Ordinary Shares	$0.27	A	628872	Acquired	2029-09-01	Ordinary Shares (628872)	Direct
2019-09-01	Option to purchase Ordinary Shares	$0.0012	A	140448	Acquired		Ordinary Shares (140448)	Direct

Footnotes

F1: The exercise price was converted from GBP0.22 based on an exchange rate of $U.S. 1.21721 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 157,218 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the first of each month from October 1, 2020 through August 1, 2023 and 13,119 Ordinary Shares on September 1, 2023.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.21721 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 35,112 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the first of each September from September 1, 2021 through September 1, 2023.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.